FDAapproval84% confidence
Understanding the Risks of Compounded Drugs
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.
Supporting Context
- Therapeutic area
- Hematology · Hemophilia A/B
- Sub-indication
- General
Related signal: FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications